Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
Abstract Background Pegylated liposomal doxorubicin (PLD), an anthracycline agent, is widely used as a treatment option for platinum‐refractory/resistant epithelial ovarian cancer (EOC). Although only a subset of patients with platinum‐refractory/resistant EOC derive benefit from PLD, predictive bio...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6086 |